Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease
NCT04232969 on ClinicalTrials.gov · last registry update 2026-05-06
A small phase 3 — 194 participants, against a typical 424. The sponsor logged completion for 24 February 2024. Primary outcome, as filed: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3. exenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P3
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University College, London
- Sponsor type
- Other
- Enrollment
- 194
- Started
- 2020-01-20
- Primary completion
- 2024-02-24 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3
Conditions studied
Parkinson's Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.